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Abstract
Purpose—The aims of this study were to examine quality of life, using the Impact of Cancer 
version 2 (IOCv2), in British non-Hodgkin lymphoma (NHL) survivors and investigate differences 
between survivors in the UK and the USA.
Methods—NHL survivors (326 UK and 667 US) completed the 37-item IOCv2 and 
psychological distress, fatigue and social support questionnaires.
Results—The IOCv2 showed good reliability in the British sample with higher internal 
consistency (Cronbach alpha 0.7–0.9) and no floor and ceiling effects. UK survivors showed 
significantly higher negative (p < 0.001) and higher positive (p = 0.003) IOC compared to US 
survivors. Younger survivors (p = 0.003), those with shorter time since diagnosis (p < 0.001) and 
with lower levels of social support (p = 0.001), showed more negative IOC in both groups. Higher 
negative IOC was also significantly associated with fatigue (p < 0.001) and depressive symptoms 
(p < 0.001) in both countries. Higher positive IOC was associated with female gender (p < 0.001), 
longer time since diagnosis (p = 0.02), those diagnosed at later stage (p < 0.05) and with greater 
social support (p = 0.004). Whereas significantly lower positive IOC was associated with white 
ethnicity (p < 0.001), higher education levels (p < 0.05) and fatigue (p = 0.001).
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Conclusions—The IOCv2 is reliable and applicable in UK and US populations. Both negative 
and positive IOC scores were higher in British compared to US survivors. However, in both 
countries, psychosocial factors consistently showed the greatest impact on QOL irrespective of 
clinical characteristics. Recognition and treatment of individuals with these risk factors is a high 
priority for improving QOL in long-term cancer survivors, as is the development of modular 
interventions aimed at increasing positive IOC as well as decreasing negative impact. The IOCv2 
shows great potential both as a screening and assessment measure for examining cancer-related 
outcomes among survivors.
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Introduction
For the ever-growing numbers of survivors, cancer is a chronic life-altering condition. As a 
case in point, non- Hodgkin lymphoma (NHL) survivors experience various adverse physical 
late effects of cancer therapy [1–3], as well as psychosocial problems, including depression 
and anxiety that affect their quality of life (QOL). Although these problems are clearly 
reported by long-term survivors [4], they have received comparatively less attention from 
researchers.
Defining and measuring QOL in cancer survivors is not straightforward. Many existing 
measures focus largely on physical symptoms related to the cancer and include generic 
symptoms such as shortness of breath or limited mobility, which could result from comorbid 
conditions. In a recent study, medical comorbidity explained more variance in health-related 
QOL than did cancer characteristics [5]. The Impact of Cancer (IOCv2) questionnaire was 
specifically designed to measure QOL in long-term cancer survivors and includes both 
positive and negative impacts of cancer. It has been used in breast and lymphoma cancer 
survivors [6]. In our recent study of British survivors of lymphoma and leukaemia (5–40-
year post-diagnosis) [7], we found the levels of depression and psychological distress in the 
survivor group were three times higher than in the general population, and these symptoms 
were significantly associated with more negative IOC scores. On the other hand, the type 
and stage of the cancer or whether there had been a recurrence showed no relationship to 
QOL, on either positive or negative IOC. Positive IOC scores showed a different pattern of 
association that reflected factors such as ethnicity, level of education and social support. 
Consequently, we need a greater understanding of how these factors interact and may differ 
in different survivor groups so that we can identify individuals with greatest needs and who 
might benefit from early psychological interventions.
In order to develop and evaluate specific health interventions for cancer patients aimed not 
only at reducing negative impacts (e.g. by identifying and treating depression) but also at 
maximising the potential to achieve and maintain positive impact using a range of therapies 
[8] (e.g. cognitive behavioural therapy, acceptance and commitment therapy [9]), we need 
reliable screening and outcome measures that are widely generalisable. Although evidence 
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for the usefulness of IOC is favourable [10–14], a comparison between UK and US samples 
would provide evidence of reproducibility of the IOC in a British population, and further 
exploration of key psychosocial and clinical factors associated with IOC scores. The aims of 
this study were thus to examine QOL in a British sample using the IOC and also investigate 
differences in IOC between US and UK NHL survivor groups, taking into account clinical 
and psychosocial factors previously shown to be associated with IOC.
Materials and methods
For the UK study, ethical approval was obtained from the National Research Ethics Service 
Ref: 11/NE/0095; for the US study, from the Institutional Review Boards of Duke University 
and the University of North Carolina at Chapel Hill (UNC). Written informed consent was 
obtained from each participant in both countries.
UK patient population
Those eligible for the study were surviving patients who had been treated at St. 
Bartholomew’s Hospital (Barts) between 1957 and 2006 with a confirmed diagnosis of 
haematological malignancy, aged ≥18 years at the time of entry into study (a proportion 
being children at the time of treatment) and ≥5 years since initial diagnosis (excluding those 
who had moved overseas, were untraceable or died prior to study commencement). Between 
September 2011 and May 2012, 1363 participants who met study eligibility criteria were 
sent a self-administered questionnaire package. Of these 1363, 718 completed the 
questionnaire (56 % responded). This study focuses on the responses from 326 NHL patients 
who participated and includes indolent NHL (29 % of all respondents) and aggressive NHL 
(17 %). The response rate for the NHL subgroup was also 56 % suggesting that they are 
representative of the entire sample.
NHL US survivors were identified through the Duke University Cancer Center and the UNC 
Lineberger Tumor Registries in November 2004 [15]. Patients were eligible if they were ≥18 
years old at diagnosis and were ≥2 years post-diagnosis. Potential participants were mailed a 
self-administered survey. Of the 1195 eligible survivors who were assumed to have received 
an invitation, 886 (74 %) returned a completed questionnaire. After excluding survivors < 5 
years post-diagnosis, 667 remained for analysis.
Total sample
To create more similar samples for comparison, we excluded survivors diagnosed < 5 years 
post-diagnosis from the US sample. The IOC was originally developed for longer-term 
survivors and thus the UK sample included only those survivors. The total sample size thus 
consisted of 993 survivors, 326 in the UK sample and 667 in the US sample (see Fig. 1).
UK questionnaire
The questionnaire included socio-demographic characteristics, in part based on the British 
Childhood Cancer Survival Study [16].
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Impact of Cancer—The British and US studies used the IOCv2, a 37-item shortened 
version of the IOC, validated in NHL survivors [10]. The IOC measures the unique positive 
and negative impacts of cancer associated with long-term survivorship [6]. Item responses 
indicate level of agreement from 1 (strongly disagree) to 5 (strongly agree) and form two 
summary scales: positive and negative impact. Scale scores are calculated by averaging the 
item scores forming the scale (high scores representing greater impact). The scales are 
subdivided into eight subscales: positive—‘Altruism/Empathy’, ‘Health Awareness’, 
‘Meaning of Cancer’ and ‘Positive Self-Evaluation,’ and negative—‘Appearance Concerns’, 
‘Body Change Concerns’, ‘Life Interferences’ and ‘Worry’. Subscale level scores are 
calculated by averaging scores of all items defining the subscale.
The Hospital Anxiety and Depression Scale (HADS) [17—Total scores on the 
HADS can range from 0 to 21 for each subscale (anxiety and depression), with lower scores 
(< 8) indicating normality and higher scores (11–21) indicating likelihood of clinical 
disorder [17].
The Chalder Fatigue Questionnaire (CFQ) [18—The CFQ measures fatigue over the 
past month and comprises 11 items with a total score range of 0–33. Higher scores represent 
more fatigue. In addition, the Social Support Inventory (SSI) [19], a 7-item validated 
instrument, was used to assess social support. The categories range from 1 (none of the time) 
to 5 (all of the time).
Socio-demographic and clinical characteristics included age, sex, educational attainment, 
ethnicity, relationship status and past history of depression and other medical conditions 
(including heart disease, high blood pressure, lung disease, non-haematological cancer or 
arthritis). Clinical details (date of diagnosis, stage of cancer and primary and follow-up 
treatments and recurrences) were obtained from the Barts Medical Oncology Unit database.
US questionnaire
In addition to the IOCv2, other measures and demographic characteristics, the US 
questionnaire included the Medical Outcomes Study Short Form SF-36. The 36 items 
represent eight subscales (physical functioning, role limitations due to physical problems, 
bodily pain, general health perceptions, vitality, social functioning, role limitations due to 
emotional problems and mental health) and two summary scores, the physical component 
(PCS) and the mental component (MCS) [19]. The scores were reversed for the convenience 
of matching with the other scales used in the UK study. Also, the Medical Outcome Study 
(MOS) Social Support Scale assessed perceived availability of social support [20]. In 
analyses, the MOS standardised index was used.
Statistical analysis
In the UK data, when calculating scale scores, the mean of non-missing items for that 
individual was imputed to replace missing items if the percentage of missing items forming 
the scale was less than 25 %. The imputation rate did not exceed 3.9 %. The HADS, SSI, 
CFQ, positive IOC and negative IOC scales had 0.97, 2.23, 1.53, 1.25 and 8.50 % missing 
scores, respectively. No imputation was done to the outcome variables in the US data.
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Probability values < 0.05 were considered statistically significant based on a two-tailed test. 
All calculations were performed using the statistical software package STATA version 12 
(Stata Corp, College Station, TX).
Distribution of the IOCv2 scale scores were studied using descriptive statistics and notched 
box and whisker plots. Floor and ceiling effects were evaluated by calculating the percentage 
of participants scoring the highest and lowest scale scores. They were considered to be 
present if more than 15 % of respondents achieve the lowest or highest possible score [21]. 
Internal consistency was checked by calculating Cronbach’s coefficient alpha (α) for each 
scale and subscale [22]. A criterion of 0.70 to 0.90 is a measure of good internal consistency 
[21]. To enhance the comparability of the UK sample to the US sample, ‘education’ was 
classified as low (no qualifications from school), medium (qualification from school or 
equivalent Higher National Certificate or vocational training) or high (high vocational 
training, university or professional qualification), and ‘comorbidities’ were grouped as none, 
1, 2 and >2 using responses regarding other medical conditions, matching the responses to 
the categorisation used in the Self-administered Comorbidity Questionnaire [23] used in the 
US sample. The socio-demographic and clinical characteristics between UK and US study 
groups were compared using chi-squared tests or Fisher’s exact test, where appropriate.
The mean IOCv2 summary scales and subscale scores of the UK and US patients were 
compared using independent sample t tests.
The respondent groups were further harmonised for psychosocial factors—depression, 
fatigue and social support—using linear transformation of all relevant scale scores into 
percentages. The HADS scores of UK respondents were matched to the Emotional well-
being domain of SF-36; CFQ scores of UK group were matched to the Energy/Fatigue 
domain of SF-36; and the UK SSI scores were matched to US MOS Social Support Survey 
index.
Two hierarchical linear regression models were used on the combined dataset to examine the 
relationship of country to positive and negative IOC after adjusting for various factors. Each 
set of factors was added to the model sequentially—at step 1, the country variable was 
added; at step 2, socio-demographics; at step 3, clinical factors relating to the cancer; at step 
4, psychosocial factors and finally at step 5, comorbidities were added. All continuous 




Socio-demographics and clinical characteristics of the 326 UK and 667 US participants are 
presented in Table 1. The two patient groups show significant differences in race, education, 
age at study, years since diagnosis, stage at diagnosis, type of treatment and self-reported 
comorbidity. Only 7 % of respondents in the UK sample were non-white compared to 14 % 
in the US sample (p < 0.001). The majority of the UK participants (56 %) had a medium 
level of education compared to 60 % of US participants having high level of education. UK 
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patients had a longer median time since diagnosis of 14.8 years compared to those in the US 
(10.0 years). However, UK patients were significantly younger (p = 0.03) at the time of 
study compared to US patients (62 vs. 64 years).
Distribution and comparison of the IOCv2 scale scores
The IOCv2 scale has high internal consistency in both the UK and US NHL groups with 
Cronbach’s alpha (α)—statistics ranging from 0.70 to 0.91 except for in the ‘Life 
interferences’ subscale in US data (α = 0.68). The floor and ceiling effects in the UK 
summary scales are compared to those in the US in Fig. 2. A relatively large number (7.4 %) 
of UK patients had a maximum score on the IOC positive scale as compared with only 
0.90 % in US group (p < 0.001). There was, however, no significant difference in minimum 
scores of negative IOC between the two groups. The UK data had slight negative skewness 
(−0.24) whereas US data were positively skewed (0.73). Table 2 shows that significant 
differences were observed in mean IOC scores between UK and US survivors in the positive 
IOC score and all positive subscale scores (p ≤ 0.02), as well as in the negative summary 
scale and all negative subscales (p < 0.001) except for in ‘Body change concerns’ (p = 0.60). 
Looking at individual comparisons, the unadjusted mean scores suggested UK survivors 
were generally more positive but also more negative about the impact of cancer compared to 
US survivors. However, they were less positive with regard to ‘Altruism and empathy’ and 
‘Positive self-evaluation’ and reported significantly less ‘Worry’ compared to US survivors.
Table 3 displays adjusted results for the positive IOC, showing that UK patients had 
significantly higher positive IOC compared to US patients after adjusting for 
sociodemographics and clinical and psychosocial factors. In addition, there was a higher 
positive IOC score among female patients, those diagnosed longer ago, and at a later stage, 
those who had chemotherapy and those with higher social support. However, there was no 
significant difference between indolent vs. aggressive NHL. Significantly lower positive 
impact was observed among patients of white race, with higher education and with higher 
levels of fatigue. As a set, the variables included in the final model explained 20 % (adjusted 
R2 = 0.18) of the variance in positive IOC scores (F = 8.63, p < 0.001).
As shown in Table 4, UK survivors had significantly higher negative IOC (p < 0.001) than 
US survivors. There was a small but significantly higher negative IOC among patients with 
higher levels of fatigue and depressive symptoms. Patients with longer time since diagnosis 
and older showed less negative IOC. Those with higher levels of social support also had 
lower negative IOC. As a set, the variables included in the final model explained 51 % 
(adjusted R2 = 0.49) of the variance in negative IOC scores (F = 35.5, p < 0.001).
Discussion
In order to investigate the reproducibility of the IOCv2 as a QOL measure in a British 
population, we assessed the distribution of the scale in a British group of long-term NHL 
survivors compared to a US sample. The scale showed good reliability in the British sample 
with high internal consistency and no floor and ceiling effects.
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We also investigated differences in IOCv2 in the two populations taking into account clinical 
factors, including histological type (indolent or aggressive), stage and treatments and 
psychosocial variables. In both countries, it was higher levels of fatigue and depressive 
symptoms that were associated with greater negative IOC rather than cancer characteristics. 
This is consistent with other reports from survivor groups [4]. Older patients, those with 
longer time since diagnosis and those with greater social support showed less negative IOC. 
Interestingly, both positive and negative IOC scores in British survivors were higher than 
among US survivors. Higher positive IOC was also reported by women, those with longer 
time since diagnosis, diagnosed at later stage and with greater social support. There was 
significantly lower positive IOC associated with white ethnicity, higher levels of education 
and those reporting higher fatigue levels.
Though these two population samples offered a unique opportunity for comparison, there 
were significant differences between them. The mean age of the British patients was lower 
and a greater proportion was under 50 years. Also, there was a greater proportion of white 
participants in the British sample. The low number of non-white participants in both studies 
makes it difficult to generalise the findings to black and minority ethnic (BME) groups and 
there were also marked cultural differences between the non-white participants from the two 
countries: the US non-white participants were predominantly African-American, whereas 
the British BME group comprised a mix of South Asian and British-African and British-
Caribbean patients.
There was also a significant difference in levels of education across the two samples, with 
US patients having a higher level of education, which may reflect differences in the 
healthcare and education systems in the two countries. In the British NHS system, treatment 
is available for all patients in a catchment area regardless of income or education, whereas in 
the US, although all patients would also receive treatment, those treated in a private health 
care system (which reflects part of the sample) may be more likely to have a higher 
education. Thus, one would expect the UK sample to have proportionately lower education 
and SES levels.
NHL stage at diagnosis was also different; UK survivors had more advanced disease at 
diagnosis. Although the British group was significantly younger, they were diagnosed longer 
ago compared to the US group and there were also differences in the treatments received by 
the two groups. However, in this study, all differences in the population and clinical 
characteristics were wee included the multivariable analyses for adjusting their effect on 
outcome variables.
A limitation of this study was the use of different scales in the US and UK samples. For 
instance, the HADS and Chalder scales are designed specifically for measurement of 
psychological distress and fatigue, respectively, whereas in the US studies, this information 
was obtained from items within the SF-36 and are therefore less sensitive at identifying US 
patients with significant problems in these areas, leading to a possible underestimation of 
clinically significant psychological distress and fatigue. Nevertheless, both depression and 
fatigue were significantly correlated with summary negative IOC in both samples, 
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emphasising the importance of taking these factors into account when addressing the 
healthcare needs of long-term cancer survivors.
The UK NHL sample size was smaller than the US but was large enough for statistical 
inference, and the UK sample was from a single centre. Although findings cannot be 
generalised to the whole survivor population in either country, the cohorts enabled analysis 
without the variability of treatment approaches inherent in a multicentre study.
After taking into account the type of cancer and other clinical and psychosocial factors, we 
found a strong association of both depression and fatigue with negative IOC in both survivor 
populations, consistent with findings from large group of UK survivors with various types of 
haematological cancer [7]. Negative impact of cancer was also greater in younger patients, 
those with a more recent diagnosis and those with less social support. These findings 
indicate the importance of screening patients for depression and fatigue so that appropriate 
psychosocial interventions to improve quality of life can be provided to those at higher risk 
(e.g. those without a support network); of course, the cross-sectional nature of this analysis 
does not allow us to rule out that depression, fatigue and less social support might be a result 
of experiencing a more negative impact of cancer. Previous studies of NHL long-term 
survivors have shown that one third of survivors experience persisting posttraumatic stress 
disorder (PTSD), with greater negative IOC being an independent predictor of PTSD 
symptoms [15, 24].
The IOC also measures positive IOC, which is not merely the inverse of negative IOC but 
appears to be influenced by different factors and may reflect posttraumatic growth and the 
underlying personality traits of individuals, such as optimism. In a comparison between the 
present group of US cancer survivors with a Dutch survivor group [11], the Dutch patients 
showed lower positive IOC scores and the authors suggested that these differences may 
reflect the difference in healthcare systems; that is, the socialised system in the Netherlands 
may result in a lower sense of personal control than in the USA where health care relies 
more on individual responsibility with a consequent feeling of more personal control and 
thus positive cancer impact in US patients. That said, the UK also has socialised healthcare 
system but, in this study, British survivors showed higher positive IOC than US patients—a 
finding that could be equally interpreted as being the effect of the support that is provided by 
a universal health care system like the NHS [25]. However, it is more likely that more 
complex reasons prevail, such as cultural differences in how cancer and chronic illness are 
perceived. Although the literature on cultural differences in cancer survivors is limited, one 
Spanish study reported a similar association between psychological distress and worsened 
QOL in breast cancer patients, but a positive effect among patients who reported having a 
‘fighting spirit’ or who used ‘denial’ as a defence mechanism [25]. Clearly, there is cause to 
more fully explore the reasons underlying differences in the impact of cancer across 
countries and culture; doing so may help identify new strategies to promote QOL among 
survivors.
Interestingly, we found that those with higher education reported lower positive IOC 
whereas there was no relationship between education and negative IOC. This finding may 
reflect that those who are more educated are also more aware of the full implications of a 
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cancer diagnosis. Relatedly, lower positive IOC was associated with white race. We need a 
greater understanding of how these factors interact in different countries and how they may 
differ in particular groups so that we can identify which individuals have greater needs and 
who would particularly benefit from early psychological interventions. Such interventions 
would be aimed not only at reducing negative IOC but also maximising the potential to 
achieve and maintain positive impact using a range of therapies [8] such as cognitive 
behavioural therapy, acceptance and commitment therapy [9]. Those reporting higher fatigue 
levels had lower positive IOC and there is increasing evidence of the beneficial effects of 
exercise therapies on cancer-related QOL [26].
Conclusions
The IOCv2 is reliable and applicable in British, as well as other European [11] and US 
populations [10]. Both the positive and negative IOC in British survivors were higher than in 
US survivors; differences in IOC between UK and US probably reflect differences in both 
cultural and healthcare systems. However, in both countries, rather than clinical 
characteristics of the cancer, it was psychosocial factors that were consistently associated 
with the greatest impact on QOL.
Recognition and treatment of individuals with these risk factors is a high priority for 
improving QOL in long-term cancer survivors, as is the development of modular 
interventions to increase positive IOC as well as to decrease negative impact. The IOCv2 
shows great potential as both a screening tool and outcome measure for evaluating complex 
interventions for cancer survivors.
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Flow diagram of the study data structure
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Floor and ceiling effects in the UK (N = 323) and US (N = 666) samples for the IOC 
positive and negative summary scales. Notched box and whisker plot showing median and 
interquartile range (IQR). The median (quartiles) positive IOC score in UK and US patients 
are 4.0 (3.3, 4.5) and 3.5 (2.9, 4.0), respectively, while the median (quartiles) negative IOC 
scores are 3.1 (2.4, 3.7) and 2.1 (1.6, 2.6), respectively
Sarker et al. Page 12
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Table 2
Comparison of mean IOCv2 scores between UK and US NHL survivors





Positive impact 3.87 (0.76) 3.47 (0.79)   0.4 <0.001
Negative impact 3.07 (0.89) 2.19 (0.73)   0.9 <0.001
Positive subscales   
  Altruism and empathy 3.65 (0.55) 3.84 (0.97) −0.2 0.02
  Health awareness 3.84 (0.70) 3.66 (0.87)   0.2 0.02
  Meaning of cancer 3.82 (0.74) 2.71 (1.08)   1.1 <0.001
  Positive self-evaluation 3.17 (0.76) 3.85 (0.98) −0.7 <0.001
Negative subscales   
  Appearance concerns 2.56 (0.70) 1.71 (0.91)   0.9 <0.001
  Body change concerns 2.21 (0.97) 2.34 (1.16) −0.1 0.60
  Life interferences 2.84 (1.05) 1.99 (0.70)   0.9 <0.001
  Worry 2.15 (0.79) 2.53 (0.99) −0.4 <0.001
*p values are corrected for multiple testing using Bonferroni method
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